Xylem (NYSE:XYL) Now Covered by Analysts at Royal Bank Of Canada

Investment analysts at Royal Bank Of Canada assumed coverage on shares of Xylem (NYSE:XYL) in a research note issued to investors on Wednesday, Zacks reports. The firm set a “moderate buy” rating on the industrial products company’s stock.

A number of other equities analysts have also commented on the company. Mizuho set a $99.00 price target on Xylem in a research note on Wednesday. Stifel Nicolaus cut their price objective on Xylem from $141.00 to $114.00 and set a “buy” rating on the stock in a research report on Wednesday. Oppenheimer dropped their price objective on Xylem from $150.00 to $135.00 and set an “outperform” rating on the stock in a research note on Wednesday. Jefferies Financial Group upped their price target on shares of Xylem from $145.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, August 24th. Finally, Wolfe Research began coverage on shares of Xylem in a report on Tuesday, September 15th. They issued a “peer perform” rating on the stock. Nine investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $122.31.

Xylem Stock Performance

NYSE:XYL opened at $88.31 on Wednesday. The stock has a 50-day simple moving average of $105.98 and a two-hundred day simple moving average of $118.05. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.61. The firm has a market capitalization of $20.62 billion, a PE ratio of 21.03, a P/E/G ratio of 1.75 and a beta of 1.00. Xylem has a 52-week low of $87.40 and a 52-week high of $154.27.

Xylem (NYSE:XYL) last released its earnings results on Tuesday, October 27th. The industrial products company reported $1.44 earnings per share for the quarter, missing analysts’ consensus estimates of $1.45 by ($0.01). The firm had revenue of $2.20 billion for the quarter, compared to analysts’ expectations of $2.28 billion. Xylem had a net margin of 11.15% and a return on equity of 11.77%. The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.37 EPS. Analysts forecast that Xylem will post 5.65 EPS for the current year.

Hedge Funds Weigh In On Xylem

Several institutional investors and hedge funds have recently modified their holdings of XYL. William Mack & Associates Inc. purchased a new position in shares of Xylem in the third quarter valued at approximately $25,000. Dunhill Financial LLC acquired a new stake in Xylem during the second quarter worth approximately $30,000. Avalon Trust Co acquired a new position in Xylem in the second quarter valued at $35,000. Orion Capital Management LLC acquired a new stake in shares of Xylem in the 2nd quarter valued at about $35,000. Finally, Aventus Investment Advisors Inc. raised its position in Xylem by 66.7% in the 2nd quarter. Aventus Investment Advisors Inc. now owns 300 shares of the industrial products company’s stock valued at $35,000 after purchasing an additional 120 shares during the last quarter. Hedge funds and other institutional investors own 87.96% of the company’s stock.

More Xylem News

Here are the key news stories impacting Xylem this week:

• Positive Sentiment: Orders increased 10% during the quarter, indicating that underlying demand remains resilient despite near-term customer caution and project-timing issues. Xylem Q3 2026 orders report
• Positive Sentiment: Management announced divestitures and a new three-segment structure intended to simplify the portfolio and improve strategic focus. The restructuring could support longer-term execution, although investors may face transition costs. Xylem announces divestitures and new segment structure
• Neutral Sentiment: Several analysts retained bullish ratings, including “buy” or “outperform,” but reduced their price targets. Citigroup cut its target to $130, BNP Paribas Exane to $135, Stifel to $114, RBC to $125 and Oppenheimer to $135. Analyst price target changes
• Negative Sentiment: Third-quarter revenue was $2.20 billion, below the approximately $2.28 billion consensus estimate and down 3% year over year. Adjusted EPS of $1.44 also narrowly missed expectations. Weak metering demand and delayed projects weighed on results. Xylem Q3 results
• Negative Sentiment: Xylem lowered its 2026 revenue and earnings outlook and issued weaker fourth-quarter expectations, signaling that customer pullbacks and operating headwinds may persist. Xylem lowers 2026 outlook
• Negative Sentiment: JPMorgan downgraded Xylem to neutral and cut its target to $90 from $118, while unusually heavy put-option activity and a reported securities-law investigation added to investor caution. JPMorgan downgrades Xylem

Xylem Company Profile

Xylem Inc (NYSE: XYL) is a global water technology company that develops products and services for the transportation, treatment, testing and efficient use of water and wastewater. Its offerings support municipal water and wastewater utilities, industrial customers, commercial facilities and residential applications.

The company’s products and solutions include water and wastewater pumps, treatment systems, dewatering equipment, smart meters, monitoring and control technologies, leak detection tools, and data-driven analytics.